Future Outlook on Cephalosporin Drugs Market by Forecast to 2021 to 2027 with In-depth Analysis of Leading Players Sanofi S.A., F. Hoffmann-La Roche AG, Lupin Limited, Teva Pharmaceutical Industries Ltd

“Coherent Market Insights announced that it’s published an exclusive report namely Global Cephalosporin Drugs Market by Manufacturers, Regions, Type, and Application, Forecast to 2027 in its research database with report summary, table of content, research methodologies, and data sources. The research study offers a substantial knowledge platform for entrants and investors as well as veteran companies, manufacturers functioning in the Worldwide Cephalosporin Drugs Market. This is an informative study covering the market with an in-depth analysis and portraying the current state of affairs in the industry.”

Get Latest Insights in Sample Report @ https://www.coherentmarketinsights.com/insight/request-sample/2893

Cephalosporin is a large group of antibiotics that belongs to a class known as beta-lactams. Cephalosporin is a wide spectrum bactericidal antibiotic used for the treatment of several bacterial infections. Cephalosporin drugs are available as both branded and generic medicines. Different generations of cephalosporin are used and preferred for different indications. The third-generation is the most prescribed and broad-spectrum antimicrobial agents useful in a variety of clinical situations. Cefotaxime and ceftizoxime have the best gram-positive bactericidal activity of the third-generation cephalosporin. Ceftazidime and cefoperazone are the only third-generation drugs that provide anti-pseudomonal coverage. Ceftriaxone’s long half-life allows for once-daily dosing, making ceftriaxone an excellent drug for outpatient antibiotic therapy of community-acquired infections.

The global cephalosporin drugs market was valued at US$ 14,240.0 million in 2019, and is expected to register a CAGR of 3.8% over the forecast period (2021-2027).

Increasing Drug Approvals and R&D Activities Projected to Drive Market Growth

Increasing approvals and launch of novel products is expected to be a major factor driving the global cephalosporin drugs market growth over the forecast period. For instance, in June 2019, Merck & Co. announced that the U.S. Food and Drug Administration (FDA) approved its supplemental New Drug Application (sNDA) for the use of ZERBAXA (ceftolozane and tazobactam) for the treatment of patients 18 years and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Increasing R&D activities has spurred growth of the cephalosporin drugs market. For instance, in November 2017, B. Braun Medical Inc. initiated a clinical trial of Cefazolin infusion evaluating the safety of 1 g and 2 g of Cefazolin in pediatric subjects. The study is in phase 4 and is expected to be completed in July 2019. Therefore, increasing research on cephalosporin drugs is expected to create a favorable environment for the cephalosporin drugs market growth over the forecast period.

Global Cephalosporin Drugs Market – Restraints

Increasing cephalosporin drug recalls by regulatory bodies is hampering the cephalosporin drugs market growth. For instance, in August 2014, Caraco Pharmaceutical Laboratories Ltd., a unit of Sun Pharmaceutical Industries Ltd., initiated a recall of multiple lots of Cephalexin capsules from the U.S. market. According to a notification by the U.S. FDA, the recall of 340,553 units of 500 mg and 113,677 units of 250 mg bottles was voluntarily initiated by the company through a letter to the regulator in June 2014 under ‘Class-II’ classification, owing to Current Good Manufacturing Practice (CGMP) deviations.

Global Cephalosporin Drugs Market – Regional Insights

North America is expected to lead the global cephalosporin drugs market throughout the forecast timeline, owing to increasing number of product launches. For instance, in August 2017, Dr. Reddy’s Laboratories Ltd. launched Cefixime for Oral Suspension, a therapeutic equivalent generic version of Suprax (cefixime) for Oral Suspension, in the U.S. market. The Suprax brand and generic had US sales of approximately US$ 50.5 million for the 12 months ended in June 2017.

Asia Pacific is expected to foresee a rapid growth in the cephalosporin drugs market. The market in Asia Pacific is expected to gain momentum during the forecast period, owing to the increasing strategic partnerships for the distribution of cephalosporin drugs. For instance, in September 2017, Basilea Pharmaceutica Ltd. announced that its subsidiary, Basilea Pharmaceutica International Ltd. (Basilea), entered into a license agreement with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. for Basilea’s antibiotic Zevtera (ceftobiprole) in China.

Major Players Are Operating In The Market: Merck & Co. Inc., GlaxoSmithKline plc., Pfizer Inc., Allergan plc., Abbott Laboratories, Basilea Pharmaceutica Ltd., Sanofi S.A., F. Hoffmann-La Roche AG, Lupin Limited, Teva Pharmaceutical Industries Ltd., and B. Braun Melsungen AG

Buy This Research Study Report (Flat US $2000 OFF) @ https://www.coherentmarketinsights.com/promo/buynow/2893

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

Contact Us

Name: Mr. Shah
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com